NCT02976194 - Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 22, 2016

Primary Completion Date

November 30, 2019

Study Completion Date

January 31, 2020

Conditions

Exudative Age-related Macular DegenerationPolypoidal Choroidal Vasculopathy

Interventions

DRUG

ranibizumab

Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.

Trial Locations (2)

Pusan National University Hospital, Busan

Pusan National University Yangsan Hospital, Yangsan